Systematic Review and Meta-analysis assessing efficacy, safety and tolerability of Perampanel for focal seizures

Published: 1 March 2022| Version 1 | DOI: 10.17632/644kwg28nd.1
Contributors:
,
,
,
,
,

Description

Perampanel is a drug approved for the treatment of pharmacoresistant focal seizures in patients aged 12 years and older. The present data was collected perform a systematic review and meta-analysis to assess its efficacy, safety and tolerability in these patients. The data describes the selection of studies as per the inclusion criteria and the risk of bias assessment of the included studies. Further, the data extracted from the included studies has also been described. This will enable the conduct of further such studies and generation of evidence based database.

Files

Categories

Clinical Neurology, Focal Epilepsy, Anti-Convulsant Drugs Treatment in Epilepsy

Licence